Purpose: To compare efficacy, safety and toxicity of indinavir and zidovudine, when administered either alone or concomitantly. Methods: This is a prospective study which has been carried out since April 1995, on 300 seropositive HIV-1 patients (599 eyes) without any opportunistic infection, and with CD4 between 50 to 250 cells/mm ³, who participated in a rando- mized double blind study. The determined efficacy parameter was the appearance of opportunistic infections. In July 1996, the patients who received only zidovudine started to receive also lamivudine. In February 1997, the study was opened and all the patients started to receive the three drugs. Results: In this study we report the ocular findings observed in the beginning of the study and the alterations which have been prospectively observed during 4 years. Three patients (4 eyes, 1.33%), who belonged to the group that received only zidovudine, developed CMV retinopathy. Conclusion: The results suggest an incidence reduction of CMV retinopathy in patients treated with protease inhibitor.
HIV-1 seropositive patients; Indinavir; Zidovudine; Lamivudine; Ocular findings in AIDS; Opportunistic infection